scispace - formally typeset
M

Michael Bachmann

Researcher at Helmholtz-Zentrum Dresden-Rossendorf

Publications -  402
Citations -  16252

Michael Bachmann is an academic researcher from Helmholtz-Zentrum Dresden-Rossendorf. The author has contributed to research in topics: Antigen & Chimeric antigen receptor. The author has an hindex of 63, co-authored 360 publications receiving 14388 citations. Previous affiliations of Michael Bachmann include ACADIA Pharmaceuticals Inc. & University of Southern California.

Papers
More filters
Journal ArticleDOI

Analysis of epitope spreading over an eleven-year period in a patient with systemic lupus erythematosus.

TL;DR: During disease flares anti-Ro/SS A antibodies were upregulated and anti-dsDNA antibodies appeared, thus supporting the concept of an antigen driven intermolecular epitope spreading to Ro/SS-A and dsDNA.
Journal ArticleDOI

GD3–7-aldehyde is an apoptosis inducer and interacts with adenine nucleotide translocase

TL;DR: GD3-7 proved to be more efficient to induce pro-apoptotic mitochondrial alterations than GD3 when tested on mouse liver mitochondria, suggesting that ANT is the molecular target of GD3-3, and might be a novel mediator of PTPC-dependent apoptosis in cancer cells.
Journal ArticleDOI

Purification and properties of a novel pyrimidine-specific endoribonuclease termed endoribonuclease VII from calf thymus that is modulated by polyadenylate.

TL;DR: Several lines of evidence suggesting a role of endoribonuclease VII in mRNA processing are presented, including a marked affinity for poly(A) and poly(U).
Journal ArticleDOI

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy.

TL;DR: In this article, a switchable, flexible and programmable adaptor reverse (Rev) CAR platform was proposed to enable combinatorial tumor targeting following Boolean logic gates, and the applicability of the RevCAR platform to target myeloid malignancies like AML was demonstrated.